Literature DB >> 18492296

Therapeutic amenorrhea in patients at risk for thrombocytopenia.

Meredith K Martin-Johnston1, Olanma Y Okoji, Alicia Armstrong.   

Abstract

To examine the need for and evaluate the method of menses suppression in women at risk for thrombocytopenia. A systematic review of the published literature in MEDLINE using the search terms thrombocytopenia, menorrhagia, therapeutic amenorrhea, progestin intrauterine device, combination oral contraceptive--extended and cyclic, gonadotropin releasing hormone agonist, danazol, and progestins. There are an increased number of reproductive age women at risk for thrombocytopenia who would benefit from menses suppression. A number of effective medical regimens are available. In patients who fail medical therapy, endometrial ablation appears to be effective in women with thrombocytopenia. As a result of the increased number of women at risk for thrombocytopenia, there is a need for therapeutic amenorrhea. The type of regimen selected depends upon the patients need for contraception and the ability to tolerate estrogen-containing medications. For women who fail medical therapy, there are surgical options, which are associated with less morbidity than hysterectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18492296      PMCID: PMC4790444          DOI: 10.1097/OGX.0b013e3181706620

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  68 in total

Review 1.  Clinical inquiries. What are contraindications to IUDs?

Authors:  Heather L Paladine; Carol E Blenning; Dolores Zegar Judkins; Shashi Mittal
Journal:  J Fam Pract       Date:  2006-08       Impact factor: 0.493

2.  ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions.

Authors: 
Journal:  Obstet Gynecol       Date:  2006-06       Impact factor: 7.661

3.  The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia.

Authors:  F Mercorio; R De Simone; A Di Spiezio Sardo; G Cerrota; G Bifulco; F Vanacore; C Nappi
Journal:  Contraception       Date:  2003-04       Impact factor: 3.375

4.  Short-term treatment of uterine fibromyomas with danazol.

Authors:  V De Leo; A la Marca; G Morgante
Journal:  Gynecol Obstet Invest       Date:  1999       Impact factor: 2.031

5.  The epidemiology of hysterectomy: findings in a large cohort study.

Authors:  M P Vessey; L Villard-Mackintosh; K McPherson; A Coulter; D Yeates
Journal:  Br J Obstet Gynaecol       Date:  1992-05

6.  Prevention of hypermenorrhea with leuprolide in premenopausal women undergoing bone marrow transplantation.

Authors:  R Ghalie; C Porter; E Radwanska; W Fitzsimmons; C Richman; H Kaizer
Journal:  Am J Hematol       Date:  1993-04       Impact factor: 10.047

Review 7.  A benefit-risk assessment of medical treatment for uterine leiomyomas.

Authors:  Vincenzo De Leo; Giuseppe Morgante; Antonio La Marca; Maria Concetta Musacchio; Massimo Sorace; Chiara Cavicchioli; Felice Petraglia
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Danazol for heavy menstrual bleeding.

Authors:  H Beaumont; C Augood; K Duckitt; A Lethaby
Journal:  Cochrane Database Syst Rev       Date:  2002

9.  Intrauterine devices and pelvic inflammatory disease: an international perspective.

Authors:  T M Farley; M J Rosenberg; P J Rowe; J H Chen; O Meirik
Journal:  Lancet       Date:  1992-03-28       Impact factor: 79.321

10.  The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.

Authors:  Sucheta A Trasi; Anil V Pathare; Shrimati D Shetty; Kanjaksha Ghosh; Vinita Salvi; Dipika Mohanty
Journal:  Ann Hematol       Date:  2004-07-30       Impact factor: 3.673

View more
  3 in total

1.  Management of uterine bleeding during hematopoietic stem cell transplantation.

Authors:  Stephanie E Purisch; Dana Shanis; Christa Zerbe; Melissa Merideth; Jennifer Cuellar-Rodriguez; Pamela Stratton
Journal:  Obstet Gynecol       Date:  2013-02       Impact factor: 7.661

2.  Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives.

Authors:  Giuseppe Benagiano; Sabina Carrara; Valentina Filippi
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

Review 3.  Menstrual suppression: current perspectives.

Authors:  Paula Adams Hillard
Journal:  Int J Womens Health       Date:  2014-06-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.